About Curtana Pharma
Curtana Pharma is a Healthcare company based in Austin (United States) founded in 2013. Small molecule therapeutics targeting transcription factors for glioblastoma are developed. Curtana Pharma offers products and services including CT-179. Its focus areas include Life Sciences, Oncology, Drugs and Brain Cancer. Its legal entity is Curtana Pharmaceuticals, Inc.
Company details
Curtana Pharma was founded in 2013 in Austin, United States, as an early-stage biopharmaceutical company. Operations center on the development of small molecule therapeutics that target transcription factors, specifically for glioblastoma multiforme. The lead candidate, CT-179, addresses the OLIG2 transcription factor, which is expressed in diffuse gliomas and associated with tumorigenic stem cells. A Pre-IND submission for CT-179 in malignant gliomas was completed in August 2017.
- Headquarters Austin, United States
- SectorsHealthcare
- Website curtanapharma.com
- Social LinkedIn
- Legal Name Curtana Pharmaceuticals, Inc.
- Latest Funding Round$55.77K (USD), Grant
May 2017
- InvestorsHHS
& 5 more
Products & Services of Curtana Pharma
Curtana Pharma offers a comprehensive portfolio of products and services, including CT-179.
Inhibitor targeting OLIG2 to treat brain cancers effectively.
Funding Insights of Curtana Pharma
- Total Rounds 8
- Last Round Grant — $55,770
- First Round $7.6M
(Aug 2014)
- Investors Count 6
All 8 funding rounds of Curtana Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2017 | $55,770 | Grant | – | – | |
| Feb 2017 | Seed | – | – | – | |
| Feb 2017 | $53,830 | Grant | – | – | |
| Jan 2017 | $52,286 | Grant | – | – | |
| Sep 2016 | Seed | – | Austin Technology Incubator | – | |
| Oct 2014 | $225,000 | Grant | – | – | |
| Sep 2014 | $225,000 | Grant | – | – | |
| Aug 2014 | $7.6M | Grant | – | – |
6 investors in total: 6 institutional.
Investors in Curtana Pharma
Curtana Pharma has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Deep tech commercialization is facilitated by Austin Technology Incubator. | 1989 | ati.utexas.edu | Austin, USA | |
| sbir.nih.gov | ||||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| cprit.texas.gov |
Investor details for Curtana Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Curtana Pharma
12 people are tracked at Curtana Pharma (2 in leadership, 9 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Gregory Stein | CEO | Leadership |
David M. Weiner | Chief Medical Officer | Leadership |
Brent Reynolds | Scientific Advisor | Board & advisors |
Frank Furnari | Scientific Advisor | Board & advisors |
Jann Sarkaria | Scientific Advisor | Board & advisors |
Santosh Kesari | Board Member | Board & advisors |
Peter Dirks | Scientific Advisor | Board & advisors |
Gary W. Pace | Board Member | Board & advisors |
Xiao-Nan Li | Scientific Advisor | Board & advisors |
Martin Simonetti | Board Member | Board & advisors |
Terrence Johns | Scientific Advisor | Board & advisors |
Daniel Pertschuk | Consultant, Clinical Development | Team |
Complete people profiles for Curtana Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Curtana Pharma
3 dated milestones of Curtana Pharma across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Curtana Pharma is founded.
- Funding First funding round of $7.6M.
- Funding Latest funding round, Grant, of $56K.
Web traffic of Curtana Pharma
The website of Curtana Pharma (curtanapharma.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 13.7% vs previous month
Top companies in Neurology
3 companies that operate in the same segment as Curtana Pharma (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Curtana Pharma
Curtana Pharma was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Curtana Pharma is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Curtana Pharma was founded in 2013 in Austin, United States, as an early-stage biopharmaceutical company. Operations center on the development of small molecule therapeutics that target transcription factors, specifically for glioblastoma multiforme. The lead candidate, CT-179, addresses the OLIG2 transcription factor, which is expressed in diffuse gliomas and associated with tumorigenic stem cells. A Pre-IND submission for CT-179 in malignant gliomas was completed in August 2017.
Curtana Pharma offers CT-179.
Curtana Pharma has 6 investors. Key investors include HHS, European Union, EIC Fund, Austin Technology Incubator, and NIH SBIR/STTR.
Curtana Pharma operates through Curtana Pharmaceuticals, Inc..